Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.
News|Articles|November 4, 2026
Conference Preview: 2026 GOLD International COPD Conference
Author(s)Tim Smith
Fact checked by: Chelsie Derman
HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.
Advertisement
Advertisement
HCPLive’s team is providing on-site coverage of the
Related to this article
In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.
Michael Wechsler, MD, discusses SWIFT/AGILE data showing 59% of patients in remission with depemokimab at year 1 maintained it at year 2.
Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.
The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.
Jean Elwing, MD, and pulmonologists from across the US discuss how risk, payer coverage, and patient resources shape PAH therapy selection.
In PHINDER, IPF had the highest PVD-B65 mortality risk scores. Rali discusses why PH in ILD is missed and when to refer for right heart catheterization.
Parth Rali, MD, explains how the AHA/ACC A-through-E categories compare with ESC risk tiers and how hospitals can meet the class 1 PERT recommendation.
Advertisement
Advertisement